Učitavanje...

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K(+)) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autor: Hayes, Keith C
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3090287/
https://ncbi.nlm.nih.gov/pubmed/21573085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S10469
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!